LCP
ALXN

Lamond Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Lamond Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,000
Closed -$15.6M – 13
2015
Q3 		$15.6M Buy
100,000
+43,390
+77% +$7.91M 11.7% 4
2015
Q2 		$10.2M Buy
+56,610
New +$9.77M 10.39% 4

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lamond Capital Partners's ALXN Position: Q4 2015 in Review

Lamond Capital Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2015, closing a stake of 100,000 shares — an estimated $15.6M sold.

Lamond Capital Partners first reported a position in ALXN in Q2 2015 and held it in 2 quarters. The position peaked at $15.6M in Q3 2015. 547 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

  • Lamond Capital Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Lamond Capital Partners sold 100,000 Alexion Pharmaceuticals shares in Q4 2015, an estimated $15.6M.
  • Lamond Capital Partners first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Lamond Capital Partners's Alexion Pharmaceuticals position peaked at $15.6M in Q3 2015.
  • 547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Lamond Capital Partners's 13F filing for Q4 2015, filed 9 Feb 2016.